Search
Search results
2106 results found
Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.
Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2020. “Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients With and Without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.”. J Parkinsons Dis.
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord 2020;77:141-145.
Bhidayasiri, R, JM Kane, KP Frei, SN Caroff, CU Correll, S Fahn, J Jankovic, RA Hauser, and DD Truong. 2020. “Expanding Phenomenologic Heterogeneity of Tardive Syndromes: Time for an Updated Assessment Tool. Parkinsonism Relat Disord 2020;77:141-145.”. Parkonsonism Relat Disord.
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.
Chen, JJ, Y Han, J Tang, L Portillo, RA Hauser, and K Dashtipour. 2018. “Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-Analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.”. Ann Pharmacother.
Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. Int J Neurosci 2017;127:841-848.
Valdes, EG, ML O’Connor, EY Uc, RA Hauser, R Andel, and JD Edwards. 2017. “Use, Maintenance and Dose Effects of Cognitive Speed of Processing Training in Parkinson’s Disease. Int J Neurosci 2017;127:841-848.”. Int J Neurosci.
Randomized Trial of Preladenant, Given as Monotherapy, in Patients with Early Parkinson Disease. Neurology 2017;88:2198-2206.
Stocchi, F, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, TW Ho, et al. 2017. “Randomized Trial of Preladenant, Given As Monotherapy, in Patients With Early Parkinson Disease. Neurology 2017;88:2198-2206.”. Neurology.
Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci 2017;377:137-143.
Chou, KL, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, GS Liang, RA Hauser, L Sudarsky, and . 2017. “Factors Associated With Falling in Early, Treated Parkinson’s Disease: The NET-PD LS1 Cohort. J Neurol Sci 2017;377:137-143.”. J Neurol Sci.
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.
Pahwa, R, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, DD Truong, P Agarwal, et al. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.”. JAMA Neurol.
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.
Hauser, RA, R Pahwa, CM Tanner, W Oertel, SH Isaacson, R Johnson, L Felt, and MJ Stempien. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.”. J Parkinsons Dis.
Communicating with participants during the conduct of multi-center clinical trials. Clin Trials 2016;13:592-596.
Augustine, EF, ER Dorsey, RA Hauser, JJ Elm, BC Tilley, and KK Kieburtz. 2016. “Communicating With Participants During the Conduct of Multi-Center Clinical Trials. Clin Trials 2016;13:592-596.”. Clin Trials.